AMWatch

Malmø-selskab henter millioninvestering før børsnotering

Ascelia Pharma med danske Magnus Corfitzen i spidsen har hentet 60 mio. svenske kroner hos blandt andre Sunstone. Investeringen skal bringe selskabet den sidste vej til et fase 3-studie, der skal finanseres via en børsnotering.

Photo: Ritzau Scanpix/AP/Evan Vucci

Malmø-baserede Ascelia Pharma har sikret sig finansieringer til at afslutte det forberedende arbejde til et kommende fase 3-studie med hovedaktivet Mangoral.

Det er sket via en finansieringsrunde, hvor de eksisterende investorer i kapitalfondene Sunstone Capital og Øresund Healthcare Management samt de øvrige aktionærer, herunder bestyrelsesmedlemmer og ledelsen, har deltaget. Derudover har selskabet hentet økonomisk opbakning hos flere private investorer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Oil services investments and inflows help BankInvest in Q1

Net inflows have exceeded expectations at BankInvest in Q1. The EUR 20bn manager has been criticized for some of the investments in its sustainable flagship product, but CEO Lars Bo Bertram is proud that the EUR 12bn fund has managed to beat its benchmark despite massive gains for oil and gas.

Latest news

AMWatch job

See all jobs

See all jobs

Watch job

See all jobs

See all jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch